Combination of the Topical Photodynamic Therapy of Chloroaluminum Phthalocyanine Liposomes with Fexinidazole Oral Self-Emulsifying System as a New Strategy for Cutaneous Leishmaniasis Treatment
Pharmaceutics · 07.04.2024 · 16 (4) · 509
DOI: 10.3390/pharmaceutics16040509 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.04.2024. Verfasst von Raphaela Ariany Silva und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de Minas Gerais, National Council for Scientific and Technological Development, Fundação de Amparo à Pesquisa do Estado de Minas Gerais—FAPEMIG.
Abstract (Originalsprache)
Cutaneous leishmaniasis (CL) is a neglected tropical disease. The treatment is restricted to drugs, such as meglumine antimoniate and amphotericin B, that exhibit toxic effects, high cost, long-term treatment, and limited efficacy. The development of new alternative therapies, including the identification of effective drugs for the topical and oral treatment of CL, is of great interest. In this sense, a combination of topical photodynamic therapy (PDT) with chloroaluminum phthalocyanine liposomes (Lip-ClAlPc) and the oral administration of a self-emulsifying drug delivery system containing fexinidazole (SEDDS-FEX) emerges as a new strategy. The aim of the present study was to prepare, characterize, and evaluate the efficacy of combined therapy with Lip-ClAlPc and SEDDS-FEX in the experimental treatment of Leishmania (Leishmania) major. Lip-ClAlPc and SEDDS-FEX were prepared, and the antileishmanial efficacy study was conducted with the following groups: 1. Lip-ClAlPc (0.05 mL); 2. SEDDS-FEX (50 mg/kg/day); 3. Lip-ClAlPc (0.05 mL)+SEDDS-FEX (50 mg/kg/day) combination; 4. FEX suspension (50 mg/kg/day); and 5. control (untreated). BALB/c mice received 10 sessions of topical Lip-ClAlPc on alternate days and 20 consecutive days of SEDDS-FEX or FEX oral suspension. Therapeutical efficacy was evaluated via the parasite burden (limiting-dilution assay), lesion size (mm), healing of the lesion, and histological analyses. Lip-ClAlPc and SEDDS-FEX presented physicochemical characteristics that are compatible with the administration routes used in the treatments. Lip-ClAlPc+SEDDS-FEX led to a significant reduction in the parasitic burden in the lesion and spleen when compared to the control group (p < 0.05) and the complete healing of the lesion in 43% of animals. The Lip-ClAlPc+SEDDS-FEX combination may be promising for the treatment of CL caused by L. major.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Products, Faculty of Pharmacy, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
- Clinical Research and Public Policy Group on Infectious and Parasitic Diseases, Instituto René Rachou, Fundação Oswaldo Cruz-FIOCRUZ, Belo Horizonte 330190-002, Brazil.
- Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte 31270-901, Brazil.
- Laboratory of Software and Instrumentation in Applied Physics and Laboratory of Electron Paramagnetic Resonance, Institute of Physics, University of Brasília, Brasília 70910-900, Brazil.
- Nanobiotechnology Laboratory, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil.
- Department of Chemistry, Center of Nanotechnology and Tissue Engineering-Photobiology and Photomedicine Research Group, Faculty of Philosophy, Sciences and Letters of Ribeirão Preto, University of São Paulo, Ribeirão Pr…
ORCID-Profile: Larissa Dutra Coelho, Ricardo Bentes Azevedo, Antônio Tedesco, Marta Gontijo Aguiar
Förderung
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais
- National Council for Scientific and Technological Development
- Fundação de Amparo à Pesquisa do Estado de Minas Gerais—FAPEMIG
- Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq
- INCT em Nanobiotecnologia—CNPq
Zitieren
APA
Silva, R. A., Damasio, D. S., Coelho, L. D., de Morais-Teixeira, E., Queiroz-Junior, C. M., Souza, P. E., Azevedo, R. B., Tedesco, A., Ferreira, L. A., Oliveira, M. C., & Aguiar, M. G. (2024). Combination of the Topical Photodynamic Therapy of Chloroaluminum Phthalocyanine Liposomes with Fexinidazole Oral Self-Emulsifying System as a New Strategy for Cutaneous Leishmaniasis Treatment. Pharmaceutics, 16(4), 509. https://doi.org/10.3390/pharmaceutics16040509
Vancouver
Silva RA, Damasio DS, Coelho LD, de Morais-Teixeira E, Queiroz-Junior CM, Souza PE, et al. Combination of the Topical Photodynamic Therapy of Chloroaluminum Phthalocyanine Liposomes with Fexinidazole Oral Self-Emulsifying System as a New Strategy for Cutaneous Leishmaniasis Treatment. Pharmaceutics. 2024;16(4):509. doi:10.3390/pharmaceutics16040509
BibTeX
@article{Silva2024,
author = {Silva, Raphaela Ariany and Damasio, Danielle Soter and Coelho, Larissa Dutra and de Morais-Teixeira, Eliane and Queiroz-Junior, Celso M and Souza, Paulo Eduardo and Azevedo, Ricardo Bentes and Tedesco, Antônio and Ferreira, Lucas Antônio and Oliveira, Mônica Cristina and Aguiar, Marta Gontijo},
title = {Combination of the Topical Photodynamic Therapy of Chloroaluminum Phthalocyanine Liposomes with Fexinidazole Oral Self-Emulsifying System as a New Strategy for Cutaneous Leishmaniasis Treatment},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {4},
pages = {509},
doi = {10.3390/pharmaceutics16040509}
}
EUVIMED